Chemosensitizing multiple drug resistance of human carcinoma by Bicyclol involves attenuated P-glycoprotein, GST-P and Bcl-2

Cancer Biology and Therapy

Volumn 5, Issue 5, 2006, Pages 536-543

  Zhu, Bing ^a   Geng, Tao Liu ^b   Yong, Mei Zhao ^a   Ruo, Su Wu ^b   Strada, Samuel J ^a  

^a UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

^b INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Bcl 2; Bicyclol; Carcinoma; Chemosensitization; GST P; Multiple drug resistance; p glycoprotein

Indexed keywords

BICYCLOL; CYTOSTATIC AGENT; DOXORUBICIN; GLUTATHIONE; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE P1; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PROTEIN BCL 2; UNCLASSIFIED DRUG; VINCRISTINE;

ARTICLE; BREAST CARCINOMA; CHEMOSENSITIVITY; CONTROLLED STUDY; CROSS RESISTANCE; DOSE RESPONSE; DRUG INHIBITION; DRUG POTENTIATION; DRUG SENSITIVITY; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; IMMUNOCYTOCHEMISTRY; MULTIDRUG RESISTANCE; SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING;

EID: 33646807161     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.5.2655     Document Type: Article

References (52)

1. Liu GT. Therapeutic effects of biphenyl dimethyl dicarboxylate (DDB) on chronic viral hepatitis B. Proc Chin Acad Med Sci Peking Union Med Coll 1987; 2:228-33.
2. Fu TB, Liu GT. Protective effects of dimethyl-4,4′-dimethoxy-5,6, 5′,6′-dimethylene dioxybiphenyl-2,2′-dicarboxylate on damages of isolated rat hepatocytes induced by carbon tetrachloride and D-galactosamine. Biome Environ Sci 1992; 5185-94.
3. Liu GT, Li Y, Wei HL, Zhang H, Xu JY, Yu LH. Mechanism of protective action of bicyclol against CCl-induced liver injury in mice. Liver International 2005; 25:872-9.
4. Li M, Liu GT. Inhibition of Fas/FasL mRNA expression and TNF-α release in concanavalin A-induced liver injury in mice by bicyclol. World J Gastroenterol 2004; 10:1775-9.
5. Liu GT. The anti-virus and hepatoprotective effect of bicyclol and its mechanism of action. Chin J New Drug Clin 2001; 10:325-7.
6. Li Y, Dai GW, Liu GT, Li Y. Effect of bicyclol on acetaminophen-induced hepatotoxicity: Energetic metabolism and mitochondrial injury in acetaminophen-intoxicated mice. Acta Pharmacol Sin 2001; 36:723-6.
7. Gu XJ. The efficacy of bicyclol in treatment of chronic hepatitis B. Chin J New Drug Clin 2004; 13:940-2.
8. Yao GB, Ji YY, Wang QH, Zhou XQ, Xu DZ, Chen XY. A randomized double-blind controlled trial of bicyclol in treatment of chronic hepatitis B. Chin J New Drug Clin 2002; 21:457-61.
9. Liu GT, Li Y, Wei HL, Lu H, Zhang H, Gao YG, Wang LZ. Toxicity of novel anti-hepatitis drug bicyclol: A preclinical study. World J Gastroenterol 2005; 11:665-71.
10. Solt D, Farber E. New principle for the analysis of chemical carcinogenesis. Nature 1976; 263:701-3.
11. Sun H, Liu GT. Chemopreventive effect of dimethyl dicarboxylate biphenyl on malignant transformation of WB-F344 rat liver epithelial cells. Acta Pharmacol Sin 2005; 26:1339-44.
12. Thorgeirsson SS, Huber BE, Sorrell S, Fojo A, Pastan I, Gottesman MM. Expression of the multidrug-resistant gene in hepatocarcinogenesis and regenerating rat liver. Science 1987; 236:1120-2.
13. Teodori E, Dei S, Garnier-Suillerot A, Gualtieri F, Manetti D, Martelli C, Romanelli MN, Scapecchi S, Sudwan P, Salerno M. Exploratory chemistry toward the identification of a new class of multidrug resistance reverters inspired by pervilleine and verapamil models. J Med Chem 2005; 48:7426-36.
14. Safa AR, Glover CJ, Sewell JL, Meyers MB, Biedler JL, Felsted RL. Identification of the multidrug resistance-related membrane glycoprotein as an acceptor for calcium channel blockers. J Biol Chem 1987; 262:7884-8.
15. Dei S, Budriesi R, Sudwan P, Ferraroni M, Chiarini A, Garnier-Suillerot A, Manetti D, Martelli C, Scapecchi S, Teodori E. Diphenylcyclohexylamine derivatives as new potent multidrug resistance (MDR) modulators. Bioorg Med Chem 2005; 13:985-98.
16. Jin J, Wang FP, Wei H, Liu G. Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine. Cancer Chemother Pharmacol 2005; 55:179-88.
17. Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, Currens MJ, Seniff D, Boyd MR. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 1988; 48:4827-33.
18. Ford JM, Bruggemann EP, Pastan I, Gottesman MM, Hait WN. Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines. Cancer Res 1990; 50:1748-56.
19. Hissin PJ, Hilf R. A fluorometric method for determination of oxidized and reduced glutathione in tissues. Anal Biochem 1976; 74:214-26.
20. Habig WH, Pabst MJ, Jakoby WB. Glutathione S-Transferases: The first enzymic step in mercapturic acid formation. J Biol Chem 1974; 249:7130-9.
21. Zhu B, Vemavarapu L, Thompson WJ, Strada SJ. Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells. J Cell Biochem 2005; 94:336-50.
22. Guichard SM, Macpherson JS, Thurston DE, Jodrell DI. Influence of P-glycoprotein expression on in vitro cytotoxicity and in vivo antitumour activity of the novel pyrrolobenzodiazepine dimer SJG-136. Eur J Cancer 2005; 41:1811-8.
23. Konopleva M, Zhao S, Hu W, Jiang S, Snell V, Weidner D, Jackson CE, Zhang X, Champlin R, Estey E, Reed JC, Andreeff M. The anti-apoptotic genes Bcl-X(L) and Bcl-2 are overexpressed and contribute to chemoresistance of nonproliferating leukaemic CD34+ cells. Br J Haematol 2002; 118:521-34.
24. Fairchild CR, Ivy SP, Kao-Shan CS, Whang-Peng J, Rosen N, Israel MA, Melera PW, Cowan KH, Goldsmith ME. Isolation of amplified and overexpressed DNA sequences from adriamycin-resistant human breast cancer cells. Cancer Res 1987; 47:5141-8.
25. Choi KH, Chen CJ, Kriegler M, Roninson IB. An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the mdr1 (P-glycoprotein) gene. Cell 1988; 53:519-29.
26. Fine RL, Patel J, Chabner BA. Phorbol esters induce multidrug resistance in human breast cancer cells. Proc Natl Acad Sci USA 1988; 85:582-6.
27. Zhan M, Yu D, Liu J, Hannay J, Pollock RE. Transcriptional repression of protein kinase Calpha via Sp1 by wild type p53 is involved in inhibition of multidrug resistance 1 P-glycoprotein phosphorylation. J Biol Chem 2005; 280:4825-33.
28. Du J, Pan Y, Shi Y, Guo C, Jin X, Sun L, Liu N, Qiao T, Fan D. Overexpression and significance of prion protein in gastric cancer and multidrug-resistant gastric carcinoma cell line SGC7901/ ADR. Int J Cancer 2005; 113:213-20.
29. Vanhuyse M, Kluza J, Tardy C, Otero G, Cuevas C, Bailly C, Lansiaux A. Lamellarin D: A novel pro-apoptotic agent from marine origin insensitive to P-glycoprotein-mediated drug efflux. Cancer Lett 2005; 221:165-75.
30. Hayes JD, Wolf CR. Molecular mechanisms of drug resistance. Biochem J 1990; 272:281-95.
31. Tacke F, Marini FC 3rd, Zhao S, McQueen T, Konopleva M, Ruvolo PP, Hu SX, Xu HJ, Andreeff M. Expression of inducible Bcl-X(S) in myeloid leukemia: Compensatory upregulation of Bcl-X(L) and Bcl-2 prevents apoptosis and chemosensitization. Cancer Biol Ther 2004; 3:340-7.
32. Liebmann JE, Hahn SM, Cook JA, Lipschultz C, Mitchell JB, Kaufman DC. Glutathione depletion by L-buthionine sulfoximine antagonizes taxol cytotoxicity. Cancer Res 1993; 53:2066-70.
33. Moscow JA, Townsend AJ, Cowan KH. Elevation of pi class glutathione S-transferase activity in human breast cancer cells by transfection of the GST pi gene and its effect on sensitivity to toxins. Mol Pharmacol 1989; 36:22-8.
34. Whelan RD, Hosking LK, Townsend AJ, Cowan KH, Hill BT. Differential increases in glutathione S-transferase activities in a range of multidrug-resistant human tumor cell lines. Cancer Communications 1989; 1:359-65.
35. Cazenave LA, Moscow JA, Myers CE, Cowan KH. Glutathione S-transferase and drug resistance. Cancer Treat Res 1989; 48:171-87.
36. Buller AL, Clapper ML, Tew KD. Glutathione S-transferases in nitrogen mustard-resistant and -sensitive cell lines. Mol Pharmacol 1987; 31:575-8.
37. Teicher BA, Holden SA, Kelley MJ, Shea TC, Cucchi CA, Rosowsky A, Henner WD, Frei E 3rd. Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II). Cancer Res 1987; 47:388-93.
38. Batist G, Tulpule A, Sinha BK, Katki AG, Myers CE, Cowan KH. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem 1986; 261:15544-9.
39. Ishikawa T, Wright CD, Ishizuka H. GS-X pump is functionally overexpressed in cis-diamminedichloroplatinum (II)-resistant human leukemia HL-60 cells and downregulated by cell differentiation. J Biol Chem 1994; 269:29085-93.
40. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SP, Deeley RG. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 1994; 54:357-61.
41. Rosenbaum C, Rohrs S, Muller O, Waldmann H. Modulation of MRP-1-mediated multidrug resistance by indomethacin analogues. J Med Chem 2005; 48:1179-87.
42. Tsuchida S, Sato K. Glutathione transferases and cancer. Crit Rev Biochem Mol Biol 1992; 27:337-84.
43. Reed JC. Bcl-2 family proteins. Oncogene 1998; 17:3225-36.
44. Andreeff M, Jiang S, Zhang X, Konopleva M, Estrov Z, Snell VE, Xie Z, Okcu MF, Sanchez-Williams G, Dong J, Estey EH, Champlin RC, Kornblau SM, Reed JC, Zhao S. Expression of Bcl-2- related genes in normal and AML progenitors: Changes induced by chemotherapy and retinoic acid. Leukemia 1999; 13:1881-92.
45. Sumantran VN, Ealovega MW, Nunez G, Clarke MF, Wicha MS. Overexpression of Bcl-XS sensitizes MCF-7 cells to chemotherapy-induced apoptosis. Cancer Res 1995; 55:2507-10.
46. Pallis M, Zhu YM, Russell NH. Bcl-x(L) is heterogenously expressed by acute myeloblastic leukaemia cells and is associated with autonomous growth in vitro and with P-glycoprotein expression. Leukemia 1997; 11:945-9.
47. 2 in cardiac myocytes. J Biol Chem 2003; 278:25542-7.
48. Grad JM, Zeng XR, Boise LH. Regulation of Bcl-xL: A little bit of this and a little bit of STAT. Curr Opin Oncol 2000; 12:543-9.
49. Miyashita T, Kitada S, Krajewski S, Horne WA, Delia D, Reed JC. Overexpression of the Bcl-2 protein increases the half-life of p21Bax. J Biol Chem 1995; 270:26049-52.
50. Kornblau SM, Vu HT, Ruvolo P, Estrov Z, O'Brien S, Cortes J, Kantarjian H, Andreeff M, May WS. BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia. Clin Cancer Res 2000; 6:1401-9.
51. Taylor JK, Zhang QQ, Wyatt JR, Dean NM. Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides. Nat biotechnol 1999; 17:1097-100.
52. Mercatante DR, Mohler JL, Kole R. Cellular response to an antisense-mediated shift of Bcl-x pre-mRNA splicing and antineoplastic agents. J Biol Chem 2002; 277:49374-82.